Smitha S. Krishnamurthi, MD, is a medical oncologist at UH Cleveland Medical Center, and Associate Professor, Medicine, Case Western Reserve University School of Medicine. She is board certified in internal medicine and medical oncology, and specializes in treatment of gastrointestinal cancersand developmental therapeutics.
Dr. Krishnamurthi is the leader of the Gastrointestinal Oncology Disease team, and Director of the Clinical Trials Office, for the Case Comprehensive Cancer Center (Case CCC).
Dr. Krishnamurthi’s research focuses on development of treatment for patients with gastrointestinal cancer. She has received training in clinical research through involvement as K12 Research Scholar at the Case CCC and AACR/ASCO Methods in Clinical Research Workshop. She has served as the principal investigator of 30 clinical trials at the Case CCC, including three Cancer Therapy and Evaluation Program studies.
On a national level, Dr. Krishnamurthi has served as the Eastern Cooperative Oncology Group’s junior investigator for the NCI Colon Cancer Task Force and the Colon Cancer Committee for the annual meeting of the American Society of Clinical Oncology. She currently serves on the Cancer Communications Committee for the American Society of Clinical Oncology.
Dr. Krishnamurthi completed her undergraduate work at Case Western Reserve University, Cleveland, Ohio, and earned her medical degree from the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania. She served her residency in the Department of Medicine at the Hospital of the University of Pennsylvania, and had a fellowship in Medical Oncology at Johns Hopkins University, Baltimore, Maryland. Dr. Krishnamurthi also took part in the Graduate Training Program in Clinical Investigation, Johns Hopkins University School of Public Health and Hygiene.
American Board of Internal Medicine - Internal Medicine
American Board of Internal Medicine - Medical Oncology
Education & Training
1989, Case Western Reserve University
Medical / Professional School(s)
1993, University of Pennsylvania School of Medicine
1994, Internal Medicine - Hospital of the University of Pennsylvania
1996, Internal Medicine - Hospital of the University of Pennsylvania
2000, Medical Oncology - Johns Hopkins Oncology Center
Colon and Rectal Cancer, Developmental Therapeutics, Gastrointestional Cancer, Liver Cancers
Awards & Recognition
- Cancer Clinical Investigator Team Leadership Award, National Cancer Institute
- Cleveland Magazine “Top Doctor” in Medical Oncology/Hematology
- Participant in AACR/ASCO Workshop on Methods in Clinical Cancer Research
- Fellow’s Grant Recipient, Sixth Annual Workshop: The Clinical Pharmacology of Anticancer Drugs, Berlex Oncology Foundation
- Fellow’s Grant Recipient, Molecular Biology in Clinical Oncology, American Association of Cancer Research
- Alpha Omega Alpha, Lemmon Prize in Medicine, American Medical Women’s Association Prize, University of Pennsylvania School of Medicine
- Summa Cum Laude, Case Western Reserve University
UH Cleveland Medical Center
Department of Medicine-Hematology and Oncology
11100 Euclid Ave
UH Chagrin Highlands Health Center
3909 Orange Pl
Seidman Cancer Center, Ste 1100
UH Westlake Health Center
960 Clague Rd
Seidman Cancer Center, Ste 1200
Development of treatment for patients with gastrointestinal cancer
Patient Satisfaction Reviews
About Our Survey
At University Hospitals, we believe in providing patients with all the information they need to make educated decisions
about their health care and to choose the right doctor to meet their needs. That is why we partner with the independent
patient satisfaction company Press Ganey to survey patients about their experiences at UH facilities and with UH physicians.
We hold ourselves to the highest standards of care and are dedicated to creating a positive patient experience for
every individual who sees a UH doctor.
There are no comments for this practitioner.
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2015, Smitha Krishnamurthi, MD did not disclose any Outside Relationships with Industry.